Cargando…

Attacking MALT1 for ABC-DLBCL therapy

Detalles Bibliográficos
Autor principal:	Krappmann, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681482/ https://www.ncbi.nlm.nih.gov/pubmed/23455231

Ejemplares similares

Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion
por: Xia, Xichun, et al.
Publicado: (2018)

Combining precision oncology and immunotherapy by targeting the MALT1 protease
por: Mempel, Thorsten R, et al.
Publicado: (2022)

IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL
por: Li, Han-Bing, et al.
Publicado: (2023)

Molecular architecture and regulation of BCL10-MALT1 filaments
por: Schlauderer, Florian, et al.
Publicado: (2018)

TRAF6 controls T cell homeostasis by maintaining the equilibrium of MALT1 scaffolding and protease functions
por: O’Neill, Thomas J., et al.
Publicado: (2023)

Malt and Grain Whisky
Publicado: (1903)

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance
por: Qiao, Li-Yan, et al.
Publicado: (2021)

Targeting Lymphomas Through MALT1 Inhibition
por: Fontan, Lorena, et al.
Publicado: (2012)

Extract Malt and Its Combinations
Publicado: (1879)

MALT1 protease activity in primary effusion lymphoma
por: Juilland, Mélanie, et al.
Publicado: (2017)

CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL
por: Kim, Joo Hyun, et al.
Publicado: (2018)

Trommer’s Extract of Malt
Publicado: (1880)

Silencing heme oxygenase-1 increases the sensitivity of ABC-DLBCL cells to histone deacetylase inhibitor in vitro and in vivo
por: Zhou, Zhen, et al.
Publicado: (2017)

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma
por: Nagel, Daniel, et al.
Publicado: (2015)

The clinicopathological characteristics of gastric cancer and precancerous conditions in gastric DLBCL and MALT lymphoma patients: a multi-center retrospective study
por: Feng, Yun, et al.
Publicado: (2023)

Immunodeficiency and CARD-BCL10-MALT1
por: Pérez de Diego, Rebeca
Publicado: (2015)

Modulation of pre-mRNA structure by hnRNP proteins regulates alternative splicing of MALT1
por: Jones, Alisha N., et al.
Publicado: (2022)

BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5
por: Oien, Derek B., et al.
Publicado: (2023)

ABC of topical therapy in inflammatory bowel disease
por: Goodsall, Thomas M, et al.
Publicado: (2020)

CCND2 mRNA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL
por: Wang, Di, et al.
Publicado: (2020)

Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis
por: Mc Guire, Conor, et al.
Publicado: (2014)

AIP augments CARMA1-BCL10-MALT1 complex formation to facilitate NF-κB signaling upon T cell activation
por: Schimmack, Gisela, et al.
Publicado: (2014)

Translational Studies Using the MALT1 Inhibitor (S)-Mepazine to Induce Treg Fragility and Potentiate Immune Checkpoint Therapy in Cancer
por: Di Pilato, Mauro, et al.
Publicado: (2023)

Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells
por: Ferch, Uta, et al.
Publicado: (2009)

Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells
por: Ferch, Uta, et al.
Publicado: (2009)

Alternative splicing of MALT1 controls signalling and activation of CD4(+) T cells
por: Meininger, Isabel, et al.
Publicado: (2016)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

Human immune disorder associated with homozygous hypomorphic mutation affecting MALT1B splice variant
por: Kutukculer, Necil, et al.
Publicado: (2021)

Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells
por: Rosenbaum, Marc, et al.
Publicado: (2019)

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

Copy of Dr. Redwood’s Report on Trommer’s Extract of Malt
por: Redwood, T.
Publicado: (1878)

MALT lymphoma meets stem cells
por: Vicente-Dueñas, Carolina, et al.
Publicado: (2012)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

DLBCL Coast to Coast
por: Tesio, Melania
Publicado: (2018)

GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022)

Masking MALT1: the paracaspase's potential for cancer therapy
por: Vucic, Domagoj, et al.
Publicado: (2009)

Unrestrained cleavage of Roquin-1 by MALT1 induces spontaneous T cell activation and the development of autoimmunity
por: Schmidt, Henrik, et al.
Publicado: (2023)

Tailoring treatment for MALT lymphoma patients: where do we stand now?
por: Johnson, Peter W., et al.
Publicado: (2017)

Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
por: Qualls, David, et al.
Publicado: (2023)

The Paracaspase MALT1 in Cancer
por: Gomez Solsona, Beatriz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c6tqh9920krof42hs7afqu22ut